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Abstract
Background: In a randomized clinical trial of early versus standard antiretroviral therapy (ART) in HIV-infected adults with a
CD4 cell count between 200 and 350 cells/mm
3 in Haiti, early ART decreased mortality by 75%. We assessed the cost-
effectiveness of early versus standard ART in this trial.
Methods and Findings: Trial data included use of ART and other medications, laboratory tests, outpatient visits,
radiographic studies, procedures, and hospital services. Medication, laboratory, radiograph, labor, and overhead costs were
from the study clinic, and hospital and procedure costs were from local providers. We evaluated cost per year of life saved
(YLS), including patient and caregiver costs, with a median of 21 months and maximum of 36 months of follow-up, and with
costs and life expectancy discounted at 3% per annum. Between 2005 and 2008, 816 participants were enrolled and
followed for a median of 21 months. Mean total costs per patient during the trial were US$1,381 for early ART and US$1,033
for standard ART. After excluding research-related laboratory tests without clinical benefit, costs were US$1,158 (early ART)
and US$979 (standard ART). Early ART patients had higher mean costs for ART (US$398 versus US$81) but lower costs for
non-ART medications, CD4 cell counts, clinically indicated tests, and radiographs (US$275 versus US$384). The cost-
effectiveness ratio after a maximum of 3 years for early versus standard ART was US$3,975/YLS (95% CI US$2,129/YLS–
US$9,979/YLS) including research-related tests, and US$2,050/YLS excluding research-related tests (95% CI US$722/YLS–
US$5,537/YLS).
Conclusions: Initiating ART in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm
3 in Haiti, consistent
with World Health Organization advice, was cost-effective (US$/YLS ,3 times gross domestic product per capita) after a
maximum of 3 years, after excluding research-related laboratory tests.
Trial registration: ClinicalTrials.gov NCT00120510
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In November 2009, the World Health Organization (WHO)
changed its guidelines to recommend starting antiretroviral
therapy (ART) in all HIV-infected patients when the CD4 cell
count is less than 350 cells/mm
3 rather than 200 cells/mm
3 on the
basis of results of the CIPRA HT-001 randomized trial conducted
in Haiti, and a post hoc analysis nested within the SMART trial
[1–3]. The panel that developed this recommendation ‘‘placed a
high value on avoiding death, disease progression and HIV
transmission over and above cost and feasibility’’ [1].
Implementing the new WHO recommendations will require
countries to prioritize allocation of limited resources for ART
medications, laboratory services, and clinic staff. At the end of
2009, 14.6 million people with HIV in low- and middle-income
countries were considered in need of ART under the current
WHO guidelines, and 5.3 million were receiving treatment [4].
Haiti has an estimated HIV prevalence of 2.2% [5]. At the end of
2009 HIV prevalence in Haiti was estimated at 120,000
individuals of whom 26,000, or 43% of those with CD4 cell
count ,350 cells/mm
3, were receiving ART [6]. Evidence of cost-
effectiveness will be a major factor in determining whether
additional funding to initiate ART among patients who qualify
under the new guidelines is an appropriate use of resources.
We conducted the first (to our knowledge) cost-effectiveness
study of early versus deferred ART alongside a prospective
randomized trial. CIPRA HT-001 demonstrated that among
HIV-1 infected patients with a CD4 cell count between 200 and
350 cells/mm
3, in a resource-poor setting after a median of 21 mo
of follow-up, early ART reduces mortality by 75% compared with
deferring ART until the CD4 cell count falls to 200 cells/mm
3 or
an AIDS-defining illness occurs [2]. We evaluated the costs
incurred in each arm of the trial and compared the incremental
cost of early ART to the mortality gain in order to determine the
economic value of early ART after a maximum of 3 y with and
without taking into account savings from excluding research-
related laboratory tests.
Methods
A randomized, open-label clinical trial of early versus standard
ART in HIV-infected adults with no history of an AIDS-defining
illness and a CD4 cell count between 200 and 350 cells/mm
3 was
conducted at the Center of the Haitian Group for the Study of
Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO) in
Port-au-Prince, Haiti. Subjects were excluded if they had a history
of an AIDS-defining illness or had previously received ART [2].
The primary study end point was survival. The study was
approved by the institutional review boards of GHESKIO, Weill
Cornell Medical College (New York, New York, US) and Brigham
and Women’s Hospital (Boston, Massachusetts, US).
Between August 2005 and July 2008, 816 participants were seen
monthly and received a package of medical services similar to that
provided to HIV-infected patients at GHESKIO [7,8]. The
median (interquartile range) CD4 cell count at baseline was 280
(250–305) cells/mm
3 in the early group and 282 (250–310) cells/
mm
3 in the standard group. Median (interquartile range) body
mass index and hemoglobin at baseline were 21.3 (19.6–23.7) and
11.5 (10.3–12.6) g/dl, respectively, for the early group and 21.0
(9.2–23.4) and 11.4 (10.3–12.5) g/dl in the standard group; there
were 28 participants with pulmonary tuberculosis in the early
group and 15 in the standard group. Demographic characteristics
were similar between groups. The median age at enrollment was
40 y, 58% were women, 39% had a secondary school or higher
education, 63% were earning ,US$100 per year, and 42% were
living with a spouse or partner. The early group initiated
lamivudine and zidovudine in a fixed-dose combination and
efavirenz within 2 wk of enrollment. The standard group started
the same first-line ART regimen when participants developed a
single CD4 cell count measurement #200 cells/mm
3 or an AIDS-
defining illness. Among the 166 participants in the standard group
who started first-line ART, the median (interquartile range) CD4
cell count at ART initiation was 160 (130–190) cells/mm
3. In the
event of treatment-limiting toxicity single-drug substitutions were
allowed.
The trial protocol required that complete blood count (CBC),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), bilirubin, and creatinine tests be conducted every 3 mo
for patients on ART. These tests are not routinely performed for
nonstudy patients on ART at GHESKIO. The CD4 cell count
was repeated for all participants every 6 mo or when clinically
prompted and a CBC was obtained with every CD4 cell count,
which is routine for patients on ART at GHESKIO.
At the second interim analysis the data safety monitoring board
(DSMB) reviewed the trial data accumulated up to May 1, 2009,
representing a median of 21-mo follow-up, and there were 23
deaths in the standard group and six in the early group (p=0.0011
by the log-rank test). There were 37 patients (5%) lost to follow-up,
18 in the standard group and 19 in the early group. On the basis of
a significant survival difference between groups, the DSMB
recommended that the trial be stopped and all participants in
the standard arm be provided with ART. There was also a
significant 2-fold higher incidence of tuberculosis (TB) in the
standard group (n=36) versus the early group (n=18) (p=0.0125
by the log-rank test).
Table 1 summarizes the unit costs used to determine treatment
costs. All costs are reported in 2009 US dollars; costs in local
currency were converted at 40.47 Haitian gourdes=US$1 [9].
Medications and Laboratory Tests
Medication use was documented in study records including start
and stop dates for each drug. ART doses were specified, and for
the remaining medications we used standard doses provided by the
study staff. The cost of ART medications was set at the US
President’s Emergency Plan for AIDS Relief (PEPFAR) price
in early 2009 [10]. The cost of TB medications was set at the
International Dispensary Association (IDA; a nonprofit distributor)
price plus 20% for importing and storage fees [11]. Other
medications were purchased approximately 50% of the time from
nonprofit distributors and 50% of the time from local distributors,
so their costs were set at the average of IDA prices and local prices
provided by the GHESKIO pharmacy.
All laboratory tests were performed on site and documented in
the study records. The unit cost of each type of laboratory test had
previously been calculated by GHESKIO accounting staff and
included labor, reagents, and equipment.
Labor and Overhead Costs
Labor costs were assigned to each visit date at GHESKIO on
the basis of the type of services provided, the average duration of
each service, and hourly labor costs using annual salaries and
benefits for each job category. Study records were abstracted to
determine dates of all clinic visits and missed visits.
Average duration of visits was measured using results from time
and motion studies conducted previously for visits to HIV
physicians (15 min), and to the sexually transmitted infection
(30 min), family planning (18 min for female and 7 min for male
patient), and counseling (20 min) units [7]. We added an additional
20 min at the first HIV physician visit and an additional 10 min at
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about adherence and quality of life using a standardized form.
Physician time spent on follow-up activities such as chart
documentation was assigned an additional 50% of the duration of
each physician visit, as described previously [7]. The durations of
other types of clinical visits were obtained from interviews. These
marginal costs were used because physicians were also conducting
research activities and were therefore working at full capacity.
Nurse, pharmacist, and fieldworker time could not be assigned
accurately to specific dates and were applied to each patient study
Table 1. Unit costs.
Cost 2009 US$
ART and TB medications (monthly cost)
First-line ART (zidovudine/lamivudine and efavirenz) 18.86
Second-line ART (abacavir, tenofovir, and lopinavir/ritonavir) 79.39
TB treatment during initiation phase (isoniazid/rifampin, ethambutol, pyrazinamide) 9.73
TB treatment during maintenance phase (isoniazid/rifampin) 3.65
Laboratory and other tests (cost per test)
CD4 cell count 30.00
Monitoring tests (ALT, AST, bilirubin, creatinine) 5.00
CBC 5.00
Tuberculosis acid fast bacilli smear 2.00
Tuberculosis culture 35.00
Chest radiograph
a 35.00
GHESKIO outpatient visits (cost per visit)
Scheduled
b or interim visit (MD cost only) 4.06
Sexually transmitted infection clinic 8.13
Prenatal clinic
c 6.15
Family planning clinic (female/male patient) 1.76/0.99
Dermatology and other clinics 4.06
Social worker individual counseling 1.02
Social worker support group 0.30
Overhead (per MD visit) 6.27
Outpatient nurse and pharmacist (cost per month)
Nurse before ART initiation 0.59
Pharmacist before ART initiation 0.27
Nurse after ART initiation 0.73
Pharmacist after ART initiation 0.72
Other Support (cost per month)
Field worker 3.21
Nutritional supplementation 24.75
Hospitalizations
Hospital services (bed, nursing, administration) per day 24.71
Hospital physician on day of admission 8.49
Hospital physician on other days 4.15
Study physician visit to hospitalized patients (includes travel time) 21.67
Specialist consultation 24.71
Major procedure
d 185.32–1,235.48
Patient and caregiver costs
Patient and caregiver time (per day) 1.75
Transportation (varies by residence zone) 0.94–7.17
aCost of radiograph and reading by radiologist conducted off-site.
bAdditional costs were incurred at initial study visit (US$5.42), study visits that included physician administration of an adherence and quality-of-life questionnaire
(US$2.71) and physician visits that included initiation of ART for standard group (US$2.71).
cMD costs were reduced by one-half beyond 2 mo postdelivery.
dOne dilation and curettage (US$185.32), one hospital birth (US$247.10), one appendectomy (US$420.06), one inguinal hernia repair (US$420.06), one leg repair
(US$420.06), one cervical lymph node biopsy (US$494.19), one removal of uterine fibroids (US$1,235.48).
doi:10.1371/journal.pmed.1001095.t001
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depending on whether the patient was on or off ART.
Overhead costs were identified from the GHESKIO budget for
HIV care and were assigned to each participant as an additional
cost for each HIV physician visit (Table 1).
Other Outpatient Costs
Participants were referred to the on-site nutrition program to
receive monthly allotments of beans, oil, flour, rice, and salt when
the study staff felt it was clinically indicated. The start date for
nutritional supplementation for each participant was abstracted
from clinic records, and it was assumed that supplementation was
provided for 6 mo from this date at a standard monthly cost
calculated by the nutrition program.
Radiographs, other tests, and procedures were included only if
there was documentation that they had occurred. The costs were
actual payments made by GHESKIO or prices provided by local
providers (Table 1). There were five visits to off-site specialists.
Hospitalization Costs
Dates of hospital admission and discharge were recorded in the
study database. We reviewed study and hospital records to
determine resource use during the hospitalization, including
intravenous fluids, supplies, medications, laboratory and radio-
graphic tests, time of hospital physicians (using results of a time
and motion study conducted at one hospital over 3 d), procedures,
and specialist consultations. Complete hospital records were
available for 66 hospitalizations and hospital discharge summaries
only were available for 18 hospitalizations. GHESKIO costs were
used for all medical supplies and labor rates. A daily cost for
hospital services (bed, nursing, and administration) and costs for
each of the seven major inpatient procedures that were recorded
were from a survey of seven private hospitals in Port-au-Prince.
The daily cost for hospital services is approximately US$25 (range
US$12–US$52), which reflects the fact that in Haiti inpatient care
is provided primarily by family caregivers (see below).
Patient and Caregiver Costs
Patient time was 1 d for any outpatient visit or day in the
hospital. Family caregiver time included 4 d for the family
member to accompany patients initiating TB treatment and 1 d
of family caregiver time for each day of hospitalization. The cost of
patient and caregiver time was the minimum wage in Haiti at the
time the study was conducted (US$1.75 per day) [12]. Transpor-
tation costs were calculated on the basis of residence zone [7].
Analysis
Each of the resources used by each patient on each day was
multiplied by the unit cost of that item, then summed to determine
total costs for the arm. There were 528,623 total patient days
observed. The costs for each arm were divided by the number of
patients in the arm to determine the mean cost per patient for the
duration of the trial; reporting costs for the entire trial period is
typical when cost-effectiveness analyses are conducted alongside
clinical trials [13,14]. Differences between arms in costs for the
duration of the trial were compared using Wilcoxon rank-sum tests
to account for potential skewness in cost data. The mean survival
time was estimated by the area under the Kaplan-Meier curve and
the mean cost was estimated by the nonparametric method of
Zhao and Tian in order to account for censoring [15,16].
Censoring occurs because patients were enrolled on different dates
but observed only until death, loss to follow-up, or the stopping
date of May 1, 2009. Analyses of mean cost must be properly
adjusted for censoring because, although the time of events (e.g.,
mortality) and the time of censoring are independent, their cost
counterparts are not (informative censoring) [15,16]. Due to this
nonstandard censoring mechanism, traditional methods such as
sample average and Kaplan-Meier estimation are inappropriate
for cost data [17]. Undiscounted, observed costs were used for
comparisons between arms. Cost-effectiveness ratios used censor-
ing-adjusted life expectancy and, following typical but not
universal practice, costs and life expectancy were both discounted
at a 3% annual rate [18–20]. Cost-effectiveness ratios were
calculated with a maximum of 3 y of follow-up because of
unreliable cost estimates beyond 3 y. Cost-effectiveness ratios were
calculated as the incremental discounted cost of the early arm
versus the standard arm divided by the incremental discounted life
expectancy of the early arm versus the standard arm. Hence these
ratios should be interpreted as comparing the cost-effectiveness of
early versus standard ART only during the trial observation
period, up to a maximum of 3 y. Confidence intervals for the cost-
effectiveness ratios were calculated using Fieller’s theorem, which
is used to calculate confidence intervals for the ratio of two means
[16,21,22]. Nonparametric bootstrapping was used to construct
cost-effectiveness acceptability curves [21].
Cost-effectiveness ratios were calculated with and without
research-related laboratory monitoring tests for ART toxicities.
We believe findings excluding research-related tests are more
policy relevant because they reflect current clinical practice and
there is evidence that the availability of these test results does not
change clinical management in resource-limited settings. The
authors of the multicenter randomized DART study conducted in
Africa concluded that ‘‘ART can be safely delivered without
routine laboratory monitoring for toxic effects’’ [23]. A GHES-
KIO study showed that the utility of routine laboratory monitoring
is minimal, rarely leading to a change in medications [24].
Therefore, ALT, AST, bilirubin, creatinine, and CBC tests are not
performed routinely for ART patients at GHESKIO. To identify
research-related laboratory tests, we first excluded tests considered
to be clinically indicated because they were (1) conducted at an
interim (nonscheduled) visit; (2) conducted prior to ART initiation;
or (3) CBC tests associated with a CD4 cell count (a CBC is
required for interpretation of the CD4 count). On the basis of the
DART study findings, we estimated that of the remaining tests
conducted at scheduled study visits 3.1% of CBC tests and 2.5% of
ALT, AST, bilirubin, and creatinine tests would have been
clinically indicated and ordered by the study physician in the
absence of the protocol requirement [23]. Research-related CBC,
ALT, AST, bilirubin, and creatinine tests were therefore
calculated as 84.1% and 37.8% of the total number of these tests
conducted in the early and standard groups, respectively.
We performed sensitivity analyses on research-related labora-
tory testing and ART cost inputs. For laboratory testing, we
considered a scenario that excluded research-related testing but
where CBC testing was performed routinely every 3 mo for all
patients on zidovudine, resulting in 79% and 36% of all tests being
considered research related in the early and standard groups,
respectively. This is a conservative assumption because hemoglo-
bin monitoring every 3 mo is recommended in WHO guidelines
only for patients with low body weight or a low CD4 cell count,
and anemia can be detected with a less expensive hematocrit test
[25]. In ART cost-sensitivity analyses, we (1) reduced the cost of
efavirenz by 50% to reflect the cost in Haiti at the beginning of
2010 versus at the time of the study, and (2) substituted tenofovir
for zidovudine in first-line regimens using the current cost of
tenofovir and adding the cost of creatinine tests every 6 mo [25],
and (3) varied the cost of second-line ART by 50%. Two-sided
Cost-Effectiveness of Early HIV Therapy
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statistical analyses were performed using SAS 9.2 (SAS Institutes).
Results
Mean total treatment costs per patient for the duration of the
study and per year in the study were US$1,381 (US$810 per year)
for early ART and US$1,033 (US$631 per year) for standard
ART, a cost difference of US$348 (US$179 per year) (p,0.0001
for study duration). After excluding research-related laboratory
tests, per patient costs were US$1,158 (US$679 per year) and
US$979 (US$604 per year), respectively, a difference of US$179
(US$75 per year) (p,0.0001 for study duration). Outpatient
treatment costs are reported in Table 2. They were 92% of the
total treatment cost in the early group and 86% in the standard
group (mean costs of US$1,271 and US$888 per patient,
respectively; p,0.0001) (Table 2). The mean cost per patient of
ART during the study was higher in the early treatment group
than the standard treatment group (US$398 versus US$81;
p,0.0001) and the early group had higher per patient nurse and
pharmacist costs during the study (mean US$33 versus US$21;
p,0.0001). Participants in the early group had fewer HIV
physician visits (mean 13.2 versus 14.6 visits; p=0.0052), lower
HIV physician visit costs (mean US$78 versus US$87; p=0
.0006),
and lower costs of non-ART medications (mean US$58 versus
US$71; p=0.0002) during the study.
Table 2. Outpatient cost per person during the trial (2009 US$).
Cost Early Treatment Mean (95% CI) n=408 Standard Treatment Mean (95% CI) n=408 p-Value*
Trial Period Yearly Trial Period Yearly
Medications
Antiretroviral therapy 398 (380–416) 218 (213–222) 81 (67–95) 38 (32–44) ,0.0001
TB medications 7 (5–9) 5 (3–6) 7 (5–9) 5 (3–7) 0.4708
Other medications 51 (48–55) 30 (28–31) 64 (59–69) 38 (35–40) ,0.0001
Total cost of medications 456 (436–476) 252 (247–257) 152 (136–169) 80 (74–87) ,0.0001
Laboratory tests
CD4 cell count 122 (114–130) 64 (61–68) 171 (160–183) 97 (91–102) ,0.0001
Liver function tests
( A L T ,A S T ,b i l i r u b i n )
157 (152–163) 92 (89–95) 63 (55–72) 34 (30–39) ,0.0001
Creatinine 53 (51–55) 31 (30–32) 21 (19–24) 12 (10–13) ,0.0001
CBC 56 (54–58) 32 (32–33) 41 (38–45) 23 (21–25) ,0.0001
Other laboratory tests 39 (34–43) 23 (20–26) 50 (44–56) 30 (26–34) 0.0237
Total cost of laboratory tests 427 (407–446) 243 (233–252) 347 (320–374) 196 (181–211) ,0.0001
Other tests
Chest radiographs 14 (11–16) 8 (6–11) 20 (17–24) 13 (10–15) 0.0214
Other noninvasive tests 2 (1–3) 1 (1–2) 3 (1–5) 3 (0–6) 0.8334
Total cost of other tests 15 (13–18) 10 (7–13) 23 (19–28) 15 (11–20) 0.0099
Outpatient care
HIV physician visits 78 (75–81) 47 (45–49) 87 (84–91) 55 (53–57) 0.0006
Nurse and pharmacist 33 (32–34) 18 (18–18) 21 (20–22) 12 (12–12) ,0.0001
Prenatal care (including home
births or miscarriages)
2 (0–3) 1 (0–1) 2 (0–3) 1 (0–1) 0.6743
Other outpatient visits 2 (2–3) 1 (1–2) 3 (2–4) 2 (1–2) 0.6040
Field workers 72 (70–75) 40 (40–40) 69 (66–72) 40 (40–41) 0.1277
Overhead
a 83 (79–86) 48 (46–50) 92 (87–96) 56 (53–58) 0.0052
Total cost of outpatient care 270 (259–280) 156 (151–160) 274 (262–286) 166 (161–170) 0.9055
Nutrition Costs 103 (97–109) 61 (56–65) 90 (84–97) 61 (55–68) 0.0057
Total outpatient health
system cost
1,271 (1,219–1,322) 721 (703–739) 888 (832–943) 519 (492–545) ,0.0001
Patient and caregiver costs
Time 26 (25–27) 15 (15–16) 29 (28–31) 18 (17–19) 0.0026
Transportation 36 (33–39) 22 (20–24) 47 (42–51) 28 (26–31) 0.0111
Total patient and
caregiver costs
62 (59–66) 38 (36–40) 76 (70–81) 46 (43–49) 0.0072
Total outpatient cost 1,333 (1,280–1,386) 759 (740–778) 963 (904–1,023) 565 (537–593) ,0.0001
aOverhead costs include administrative salaries and benefits, monitoring and evaluation, building and equipment cleaning and maintenance, electricity, transportation
and storage of medications, security services, computers, furniture, office supplies, and telephone.
*p-Values are for trial period and were computed by Wilcoxon rank sum tests.
doi:10.1371/journal.pmed.1001095.t002
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research-related) versus 3,380 in the standard group (17%
research-related), and 12,841 ALT and AST, bilirubin, and
creatinine tests were performed (91% research-related) versus
5,183 in the standard arm (46% research-related). Mean costs per
patient during the study for these tests in the early group were
higher including research-related tests (US$266 versus US$126;
p,0.0001), and lower excluding research-related tests (US$43
versus US$72; p,0.0001). Fewer CD4 cell counts were
conducted in the early group (1,659 versus 2,330) leading to a
lower mean cost per patient during the study (US$122 versus
US$171; p,0.0001). The early group also had significantly lower
costs for other laboratory tests and chest radiographs. The total
per patient cost for non-ART medications, CD4 cell counts,
clinically indicated tests, and radiographs during the study was
about 30% lower in the early group (US$275 versus US$384;
p,0.0001).
Hospitalization comprised 3% of the total cost for the early
group and 6% for the standard group (mean costs per patient
during the study of US$44 and US$63 respectively; p=0.2388).
There were 84 hospitalizations during the study, 36 in the early
group and 48 in the standard group; a total of 28 patients were
hospitalized in the early group and 37 patients in the standard
group. One private hospital in Port-au-Prince was the primary site
for hospital referrals, accounting for 63 hospitalizations represent-
ing 82% of days that patients spent in the hospital. Reasons for
hospitalizations included TB (seven early group, 11 standard
group), gastroenteritis (five early group, 11 standard group),
anemia (six early group, six standard group), pneumonia (one early
group, four standard group), and other indications (17 early group,
16 standard group). The median length of stay per hospitalization
was shorter for the early treatment group (7.5 d versus 10.0 d), but
costs per hospitalization were similar between the two groups
(US$543 for the early treatment group versus US$590 for the
standard treatment group; p=0.6033) (Table 3). Patient and
caregiver costs incurred as either an outpatient or an inpatient
composed 5% of the total per patient cost for the early group and
8% of the total per patient cost for the standard group (mean
US$66 and US$82, respectively; p=0.0059).
The discounted mean survival time after a maximum of 3 y
after adjusting for censoring was 1,035 d (2.84 y) in the early
group and 998 d (2.73 y) in the standard group. The discounted
cost of treatment after adjusting for censoring was US$1,965 per
patient for the early group and US$1,555 per patient for the
standard group including research-related laboratory tests (an
incremental difference of US$410); excluding these tests the costs
were US$1,660 and US$1,448 per patient respectively (an
incremental difference of US$212). The cost-effectiveness ratio
for early versus standard ART after a maximum of 3 y was
US$3,975/year of life saved (YLS) (95% CI US$2,129/YLS–
US$9,979/YLS) including research-related tests, and US$2,050/
YLS excluding research-related tests (95% CI US$722/YLS–
US$5,537/YLS) (Table 4). Cost-effectiveness acceptability curves
were consistent with these mean and 95% CI results (Figure 1).
When we assumed routine CBC testing was performed every
3 mo for all patients on zidovudine the cost-effectiveness ratio
excluding research-related tests was US$2,264/YLS (95% CI
US$876/YLS–US$5,978/YLS). The cost-effectiveness ratios in-
cluding research-related tests were slightly lower using the current
efavirenz cost and after reducing the second-line therapy cost;
these ratios were higher when tenofovir was substituted for
zidovudine and after increasing the second-line therapy cost. In
the best case, (excluding research-related tests, using the current
efavirenz cost and reducing the second-line therapy cost) the cost-
effectiveness ratio was US$1,013/LY (95% CI cost-saving
US$3,326/YLS) (Table 4).
Table 3. Inpatient cost per hospitalization (2009 US$).
Cost
Early Treatment Mean
(95% CI) n=36
Standard Treatment Mean
(95% CI) n=48 p-Value*
Medical Products
Medications 29 (0–59) 32 (8–56) 0.2903
Intravenous fluids, blood transfusions, oxygen 27 (15–38) 22 (15–28) 0.2328
Total cost of medical products 56 (24–88) 54 (27–80) 0.8247
Tests and procedures
Laboratory tests 11 (4–17) 15 (8–23) 0.4861
Radiographs and other noninvasive tests 13 (3–24) 15 (5–26) 0.5971
Procedures
a 63 (0–139) 25 (0–53) 0.9168
Total cost of tests and procedures 87 (9–165) 56 (25–86) 0.5660
Physician visits 58 (33–82) 71 (48–95) 0.3922
Hospital services (administration,
nursing, bed)
296 (155–437) 355 (255–455) 0.2713
Total health system cost 497 (306–688) 536 (393–679) 0.5907
Patient and caregiver costs
Time 41 (22–61) 50 (36–64) 0.2713
Transportation 5 (4–6) 4 (3–5) 0.3252
Total patient and caregiver costs 46 (26–66) 54 (40–68) 0.2923
Total Inpatient Cost 543 (334–752) 590 (434–747) 0.6033
aIncludes major procedures and other procedures such as thoracentesis or insertion of nasogastric tube costing ,US$10.
*p-Values were computed by Wilcoxon rank sum tests.
doi:10.1371/journal.pmed.1001095.t003
Cost-Effectiveness of Early HIV Therapy
PLoS Medicine | www.plosmedicine.org 6 September 2011 | Volume 8 | Issue 9 | e1001095Discussion
We evaluated the costs incurred in each arm of the CIPRA HT-
001 trial and compared the incremental cost and survival benefit
of early versus standard ART in order to determine the cost-
effectiveness of early ART over a maximum 3-y time horizon.
Higher ART and associated nursing and pharmacist costs in the
early ART group were partially offset by higher costs for HIV
physician visits, other medications, CD4 cell counts, clinically
indicated laboratory tests, and radiographs in the standard group.
These are the only data, to our knowledge, comparing the cost
of early versus standard ART using data from a randomized trial
that compared these two strategies. HIV treatment protocols,
laboratory tests, and medication costs are similar to those in other
resource-poor settings, particularly programs funded in part by US
President’s Emergency Plan for AIDS Relief (PEPFAR). Our
findings are also generalizable to nontrial settings, as the patients
in the CIPRA HT-001 trial received nearly identical medical
services as nonstudy patients, with similar frequencies of physician
and nurse contacts compared to those previously described for
usual care at GHESKIO [7].
The WHO-CHOosing Interventions that are Cost Effective
(CHOICE) Working Group designates interventions as cost-
effective if the cost per disability-adjusted life year (DALY) averted
is less than three times the country’s per capita gross domestic
product (GDP) and very cost-effective if the cost per DALY is less
than one times the country’s GDP per capita [26]. Between and
even below these thresholds, each country needs to consider what
interventions to fund and how to obtain additional financial
support to expand coverage. Although our analysis computes cost-
effectiveness ratios in terms of YLS rather than using DALYs, the
WHO threshold provides general guidance that has been used in
Table 4. Cost-effectiveness of earlier initiation of ART after a maximum of 3 y.
Strategy
Mean (95% CI) Cost of
Treatment (2009 US$)
Mean (95% CI) Days
Survival Time (d)
Mean (95% CI) Incremental Cost-
Effectiveness Ratio (2009 US$/YLS)
a
Including protocol-driven
laboratory costs
Standard treatment group 1,555 (1,424–1,686) 998 (978–1,018)
Early treatment group 1,965 (1,908–2,022) 1,035 (1,025–1,045) 3,975 (2,129–9,979)
Excluding protocol-driven
laboratory tests
Standard treatment group 1,448 (1,332–1,564) 998 (978–1018)
Early treatment group 1,660 (1,601–1,719) 1,035 (1,025–1,045) 2,050 (722–5,537)
Sensitivity analyses including
protocol-driven laboratory costs
Current efavirenz cost
b
Standard treatment group 1,508 (1,383–1,633) 998 (978–1,018)
Early treatment group 1,817 (1,756–1,878) 1,035 (1,025–1,045) 3,904 (1,423–7,707)
Substituting tenofovir for zidovudine
with creatinine testing twice annually,
current tenofovir cost
Standard treatment group 1,565 (1,432–1,698) 998 (978–1,018)
Early treatment group 2,002 (1,943–2,061) 1,035 (1,025–1,045) 5,289 (2,307–15,593)
50% lower cost of second-line ART
Standard treatment group 1,555 (1,424–1,686) 998 (978–1,018)
Early treatment group 1,959 (1,902–2,016) 1,035 (1,025–1,045) 3,918 (2,091–9,841)
50% higher cost of second-line ART
Standard treatment group 1,555 (1,424–1,686) 998 (978–1,018)
Early treatment group 1,971 (1,912–2,030) 1,035 (1,025–1,045) 4,982 (2,166–10,118)
Sensitivity analyses excluding
protocol-driven laboratory costs
Quarterly CBC testing while on
zidovudine/lamivudine
Standard treatment group 1,456 (1,338–1,574) 998 (978–1,018)
Early treatment group 1,688 (1,629–1,747) 1,035 (1,025–1,045) 2,246 (876–5,978)
Current efavirenz cost
b and 50%
lower cost of second-line ART
Standard treatment group 1,401 (1,289–1,513) 998 (978–1,018)
Early treatment group 1,506 (1,447–1,565) 1,035 (1,025–1,045) 1,013 (cost-saving–3,326)
All results are rounded to the nearest integer.
aConfidence intervals for the cost-effectiveness ratios were calculated using the Fieller’s theorem for the ratio statistics [16,21,22].
b50% reduction in cost of efavirenz.
doi:10.1371/journal.pmed.1001095.t004
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US$2,355/YLS in 2009 [29]. The cost-effectiveness ratio of early
versus standard ART was above this threshold if research-related
tests were included (US$3,975/YLS), but below the threshold if
research-related tests were excluded (US$2,050/YLS). More
aggressive monitoring for anemia on zidovudine slightly increa-
sed the cost-effectiveness ratio, while substituting tenofovir for
zidovudine or using a higher cost second-line ART regimen
resulted in more substantial increases in the cost-effectiveness
ratio. Recent trends, however, indicate that costs for tenofovir and
second-line regimens are declining [30].
These cost-effectiveness ratios are highly conservative (biased
against early ART), because they do not include the clinical
benefits of earlier treatment that would continue beyond the
maximum 3-y time horizon of our study. The median CD4 cell
count at ART initiation was 280 cells/mm
3 in the early group
and 166 cells/mm
3 in the standard group. Multiple studies have
demonstrated that higher baseline CD4 cell counts are associated
with improvements in immunologic recovery and lower long-
term mortality on ART [31–33]. In contrast, a significant
proportion of patients who defer ART until the CD4 cell count
drops below 200 cells/mm
3 will fail to achieve a normal CD4 cell
count and will experience a higher rate of morbidity and
mortality from both AIDS- and non-AIDS–related diseases,
even after 7 to 10 y of otherwise effective therapy [31,34–36].
Additional benefits of earlier treatment that were not measured
include averted cases of TB among contacts of the participants
associated with the lower rate of active TB infection in the early
group, and the reduction in HIV transmission with earlier
initiation of ART [37,38].
Our study results are important for low- and middle-income
countries to consider as they decide whether to adopt the new
WHO guidelines. ART costs in the standard group were US$81 per
person over the median follow-up time of 21 mo because, even
through these participants did not initiate ART early, 39% of them
subsequently had a CD4 cell count measurement #200 cells/mm
3
or developed an AIDS-defining illness and initiated ART. ART
costs in the early group were US$317 higher (US$398 per person),
but these incremental ART costs were partly offset by savings in the
cost of non-ART medications, CD4 cell counts, clinically indicated
tests, and radiographs. In countries that have access to similar ART
prices but have higher labor rates and a more developed hospital
infrastructure, care cost savings might be greater.
To our knowledge, this is the first cost-effectiveness study of
early versus deferred ART eligibility thresholds conducted
alongside a prospective randomized trial. The trial was designed
to minimize loss to follow-up in order to obtain valid study
endpoints in both arms, and therefore does not take into account
Figure 1. Cost-effectiveness acceptability curves for earlier initiation of ART after a maximum of 3 y including and excluding
protocol-driven costs. Curves were constructed from 100 bootstrap simulations including protocol-driven costs and 100 bootstrap simulations
excluding protocol-driven costs.
doi:10.1371/journal.pmed.1001095.g001
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with a CD4 cell count above a threshold for ART initiation are
much more likely to be lost to follow-up than those who can
initiate treatment immediately [39,40]. Patient adherence to
medications and physician adherence to guidelines in a clinical
trial setting may also differ from nontrial settings [41]. Neverthe-
less, our findings are similar to published results from a computer
simulation model of HIV disease in the medium term that
conducted sensitivity analyses addressing these issues. Walensky et
al. found that in South Africa, the incremental cost-effectiveness
ratio for initiating ART at a threshold of 350 cells/mm
3 was
US$2,400/YLS compared with initiating ART at 250 cells/mm
3,
when measured over a 5-y time horizon [27]. In a study conduc-
ted in Morocco, initiating ART .200 cells/mm
3 had a cost-
effectiveness ratio that was nearly three times GDP per capita
when measured over a 5-y time horizon [42]. Although longer
follow-up is not feasible in a clinical trial, several computer
simulation results show that the cost-effectiveness of earlier ART is
lower with a lifetime perspective: US$1,200/YLS and US$616/
QALY in South Africa and US$1,530/YLS in India [27,28,43].
The long-term cost-effectiveness of early versus standard ART in
this study will depend on whether the early group continues to
have a survival benefit after standard group patients have initiated
ART and whether there are any differences in second-line ART
initiation rates between the two groups in the future; these data are
currently being collected.
Beyond the absence of long-term follow-up, our study has
additional limitations. We report years of life saved because there
are no data on disability or quality-of-life measures for patients
with early HIV disease in Haiti. If we had, earlier treatment
would likely have been even more cost-effective, because the
quality of life benefit of avoiding the 18 additional cases of TB
that occurred in the standard group would outweigh the small
number of additional drug-related adverse events observed in the
early group [2]. The cost-effectiveness ratio was lower when we
excluded research-related tests. We are confident on the basis of
results of a large randomized trial [23] and GHESKIO clinic
data [24] that clinical outcomes would have been unchanged in
the absence of these tests. Although our study was conducted at
one site, many of our findings will be generalizable to other
resource-poor settings because we use similar treatment protocols.
Our study only addresses relatively short-term costs, i.e., up to a
maximum of 3 y. Follow-up data on patient survival, new
treatment protocols (such as introduction of targeted HIV viral
load monitoring) [25], and costs will allow us to address long-
term economic outcomes.
There are substantial budget and logistical constraints to
implementing earlier treatment, including ensuring priority access
to ART for the sickest patients and not diverting resources away
from identifying these patients and retaining them in care.
Furthermore, the results of cost-effectiveness analyses should only
be one element in the priority setting process in the face of budget
constraints. On the other hand, the CIPRA HT-001 trial was
stopped because earlier treatment substantially decreased mortal-
ity [2], and our economic analysis indicates that it can be cost-
effective in resource-poor settings.
Initiating ART in HIV-infected adults with a CD4 cell count
between 200 and 350 cells/mm
3 in Haiti is cost-effective after
excluding laboratory monitoring without clinical benefit. Financial
and operational resources should be prioritized so that resource-
poor countries are able to implement the new WHO guidelines,
which recommend treatment for all HIV-infected patients with
CD4 cell counts ,350 cells/mm
3.
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Background. AIDS has killed more than 25 million people
since 1981, and about 33 million people (most of them living
in low- and middle-income countries) are now infected with
HIV, the virus that causes AIDS. HIV destroys immune system
cells (including CD4 cells, a type of lymphocyte), leaving
infected individuals susceptible to other infections. Early in
the AIDS epidemic, most HIV-infected people died within 10
years of infection. Then, in 1996, highly active antiretroviral
therapy (ART) became available and, for people living in
affluent countries HIV/AIDS became a chronic condition.
However, ART was extremely expensive and so a diagnosis of
HIV infection remained a death sentence for people living in
developing countries. In 2003, this situation was declared a
global health emergency, and governments, international
agencies, and funding bodies began to implement plans to
increase ART coverage in developing countries. In 2009,
more than a third of people in low- and middle-income
countries who needed ART were receiving it, on the basis of
guidelines that were in place at that time.
Why Was This Study Done? Until recently, the World
Health Organization (WHO) recommended that all HIV-
positive patients with CD4 cell count below 200/mm
3
blood or an AIDS-defining illness such as Kaposi’s sarcoma
should be given ART. Then, in 2009, the CIPRA HT-001
randomized clinical trial, which was undertaken in Haiti,
reported that patients who started ART when their CD4 cell
count was between 200 and 350 cells/mm
3 (‘‘early ART’’) had
a higher survival rate than patients who started ART
according to the WHO guidelines (‘‘standard ART’’). As a
result, WHO now recommends that ART is started in HIV-
infected people when their CD4 cell count falls below 350
cells/mm
3. But is this new recommendation cost-effective?
Do its benefits outweigh its costs? Policy-makers need to
know the cost-effectiveness of interventions so that they can
allocate their limited resources wisely. A medical intervention
is generally considered cost-effective if it costs less than
three times a country’s per capita gross domestic product
(GDP) per year of life saved (YLS). In this study, the
researchers assess the cost-effectiveness of early versus
standard ART in the CIPRA HT-001 trial.
What Did the Researchers Do and Find? The researchers
used trial data on the use and costs of ART, other
medications, laboratory tests, outpatient visits, radiography,
procedures, and hospital services to evaluate the costs
associated with early ART and standard ART among the 816
CIPRA HT-001 trial participants. The average total costs per
patient after a maximum of 3 years treatment were US$1,381
for early ART and US$1,033 for standard ART. These figures
dropped to US$1,158 and US$979, respectively, when the
costs of research-related tests without clinical benefit were
excluded. Patients who received early ART had higher
average costs for ART but lower costs for other aspects of
their treatment than patients who received standard ART.
The incremental cost-effectiveness ratio after 3 years for early
ART compared to standard ART was US$3,975/YLS if the
costs of research-related tests were included in the
calculation. That is, the cost of saving one year of life by
starting ART early instead of when the CD4 cell count
dropped below 200/mm
3 was nearly US$4,000. Importantly,
exclusion of the costs of research-related tests reduced the
incremental cost-effectiveness ratio of early ART compared
to standard ART to US$2,050/YLS.
What Do These Findings Mean? Because the Haitian GDP
per capita is US$785, these findings suggest that, in Haiti,
early ART is a cost-effective intervention over a 3-year period.
That is, the incremental cost per year of life saved of early
ART compared to standard ART after exclusion of research-
related tests is less than three times Haiti’s per capita GDP.
The researchers note that their incremental cost-
effectiveness ratios are likely to be conservative because
they did not consider the clinical benefits of early ART that
continue beyond 3 years—early ART is associated with lower
longer-term mortality than standard ART—or the effect of
early ART on disability and quality of life. Cost-effectiveness
studies now need to be undertaken at different sites to
determine whether these findings are generalizable but, for
now, this cost-effectiveness study suggests that the new
WHO guidelines for ART initiation can be cost-effective in
resource-poor settings, information that should help policy-
makers in developing countries allocate their limited
resources.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001095.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the HIV/AIDS in the Caribbean, and on HIV/AIDS
treatment and care (in English and Spanish)
N WHO provides information about universal access to AIDS
treatment (in English, French and Spanish); its 2010 ART
guidelines can be downloaded
N More information about the CIPRA HT-001 clinical trial is
available
N Patient stories about living with HIV/AIDS are available
through Avert and through the charity website Healthtalk-
online
N More information about GHESKIO is available from Weill
Cornell Global Health
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